Born out of Omega push for pandemic treatments, Aerium Therapeutics enters long Covid R&D
Aerium Therapeutics, which Omega Funds seeded in 2021 and unveiled in spring 2022 to take on Covid-19 with new monoclonal antibodies, will attempt to treat long Covid with a Phase II trial set to start later this month.
The move comes as the National Institutes of Health kicks off a slate of studies testing potential treatments and medical devices for long Covid, a lingering condition of the pandemic that most biopharmas have avoided. It also comes as Axcella Therapeutics said Thursday it continues searching for alternatives to take forward its long Covid treatment candidate, which failed a Phase II last year but got clearance from FDA for additional testing in a Phase IIb/III trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.